Skip to main content

Advertisement

SpringerLink
Log in

The curability of breast cancer and the treatment of advanced disease

  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Breast cancer represents a major health problem, with more than 1,000,000 new cases and 370,000 deaths yearly worldwide. In the last decade, in spite of an increasing incidence, breast cancer mortality has been declining in the majority of developed countries. This is the combined result of better education, widespread screening programmes and more efficacious adjuvant treatments. Better knowledge of breast cancer biology now allows the cosmetic, physical and psychological consequences of radical mastectomy to be spared in the majority of breast cancer patients. Use of the sentinel node technique is rapidly expanding and this will further reduce the extent and the consequences of surgery. Several clinico-pathological factors are used to discriminate between patients at low (<10%), average (10–40%) and high risk of relapse. Nodal status, tumour size, tumour grade and age are accepted universally as important factors to define risk categories. Newer factors such as uPA/PAI-1, HERer2-neu, proliferative indices and gene expression profile are promising and will allow better discrimination between patients at different risk. Endocrine manipulation with tamoxifen, ovarian ablation or both is the preferred option in the case of endocrine-responsive tumours. Tamoxifen administered for 5 years is the standard treatment for postmenopausal patients; tamoxifen plus ovarian ablation is more effective than tamoxifen alone for premenopausal women. Recent data demonstrate that, for postmenopausal patients, the aromatase inhibitors are superior to tamoxifen, with a different safety profile. At present, anastrozole can be used in the adjuvant setting in cases of tamoxifen intolerance or toxicity. Chemotherapy is the treatment of choice for steroid receptor-negative tumours. Polychemotherapy is superior to single agents and anthracycline-containing regimens are superior to CMF. Six courses of FEC or FAC or the sequential administration of four doses of anthracycline followed by four of CMF are the recommended regimens. New regimens including the taxanes have produced a further improvement in risk reduction and are reasonable therapeutic options. The taxanes have been approved for adjuvant therapy in the USA, while European approval is pending. Combined endocrine–chemotherapy is the standard adjuvant treatment in high-risk patients with endocrine-responsive tumours. Endocrine manipulation is usually administered after completion of the chemotherapy programme. For HER2-neu overexpressing tumours, several rapidly accruing trials are exploring the potential additive effect of trastuzumab, a monoclonal antibody directed against the extramembrane portion of the HER2 receptor. Primary chemotherapy is increasingly used in the treatment of locally advanced and operable breast cancer, with increased rates of breast-conserving surgery. A proportion of patients achieve a pathological complete response and these patients have significantly better long-term outcomes. Twenty-five to forty percent of breast cancer patients develop distant metastases. At this stage the disease is incurable; however, treatments can assure a significant prolongation of survival, symptomatic control and maintenance of quality of life. In the case of hormone receptor positivity and in the absence of visceral, life-threatening disease, endocrine manipulation is the treatment of choice. Active treatments include tamoxifen, ovarian ablation, aromatase inhibitors, pure anti-oestrogens and progestins. Aromatase inhibitors are the most active agents, but the choice and the sequence of endocrine therapies are also dictated by prior adjuvant treatment. Chemotherapy has to be preferred in cases of receptor-negative tumours, acquired resistance to hormones and aggressive visceral disease. Combination regimens are usually associated with higher response rates and sometimes survival prolongation, and this approach should be recommended in young patients with good performance status and visceral disease. On the other hand, single agents have a better tolerability profile and should be the treatment of choice when a careful balance between activity and tolerability is needed. For HER2-neu positive tumours, the combination of trastuzumab and chemotherapy is significantly superior to chemotherapy alone in terms of both response rates and survival. Other useful palliative treatments include bisphosphonates for the control of metastatic bone disease and radiotherapy for painful bone lesions or local relapses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, version 1.0. IARC CancerBase No. 5. Lyon: IARC Press, 2001.

  2. Ferlay J, Bray F, Sankila R, Parkin DM. EUCAN: cancer incidence, mortality and prevalence in the European Union 1998, version 5.0. IARC CancerBase No. 4. Lyon: IARC Press, 1999.

  3. Arriagada R, Le MG, Rochard F, Contesso G. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. J Clin Oncol 1996; 14:1558–1564.

    CAS  PubMed  Google Scholar 

  4. Veronesi U, Banfi A, Salvadori B, et al. Breast conservation is the treatment of choice in small breast cancer: Long-term results of a randomized trial. Eur J Cancer 1990; 26:668–670.

    CAS  PubMed  Google Scholar 

  5. Jacobson JA, Danforth DN, Cowan KH, d’Angelo T, Steinberg SM, Pierce L, Lippman ME, Lichter AS, Glatstein E, Okunieff P. Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med 1995; 332:907–911.

    Article  CAS  PubMed  Google Scholar 

  6. Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1995; 333:1456–1461.

    CAS  PubMed  Google Scholar 

  7. van Dongen JA, Bartelink H, Fentiman IS, Lerut T, Mignolet F, Olthuis G, van der Schueren E, Sylvester R, Winter J, van Zijl K. Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 trial. J Natl Cancer Inst Monogr 1992; 11:15–18.

    PubMed  Google Scholar 

  8. Fisher B, Redmond C. Lumpectomy for breast cancer: an update of the NSABP experience. National surgical adjuvant breast and bowel project. J Natl Cancer Inst Monogr 1992; 11:7–13.

    PubMed  Google Scholar 

  9. Kurtz JM, Jacquemier J, Amalric R, Brandone H, Ayme Y, Hans D, Bressac C, Spitalier JM. Breast-conserving therapy for macroscopically multiple cancers. Ann Surg 1990; 212:38–44.

    CAS  PubMed  Google Scholar 

  10. Park CC, Mitsumori M, Nixon A, Recht A, Connolly J, Gelman R, Silver B, Hetelekidis S, Abner A, Harris JR, Schnitt SJ. Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence. J Clin Oncol 2000; 18:1668–1675.

    CAS  PubMed  Google Scholar 

  11. De Naeyer B, De Meerleer G, Braems S, Vakaet L, Huys J. Collagen vascular diseases and radiation therapy: a critical review. Int J Radiat Oncol Biol Phys 1999; 44:975–980.

    Article  PubMed  Google Scholar 

  12. Pierce LJ, Strawderman M, Narod SA, Oliviotto I, Eisen A, Dawson L, Gaffney D, Solin LJ, Nixon A, Garber J, Berg C, Isaacs C, Heimann R, Olopade OI, Haffty B, Weber BL. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 2000; 18:3360–3369.

    CAS  Google Scholar 

  13. Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997; 15:2345–2350.

    CAS  PubMed  Google Scholar 

  14. Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, Feldman S, Kusminsky R, Gadd M, Kuhn J, Harlow S, Beitsch P. The sentinel node in breast cancer: a multicenter validation study. N Engl J Med 1998; 339:941–946.

    CAS  PubMed  Google Scholar 

  15. Spyratos F, Bouchet C, Tozlu S, Labroquere M, Vignaud S, Becette V, Lidereau R, Bieche I. Prognostic value of uPA, PAI-1 and PAI-2 mRNA expression in primary breast cancer. Anticancer Res 2002; 22:2997–3003.

    CAS  PubMed  Google Scholar 

  16. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177–182.

    CAS  PubMed  Google Scholar 

  17. Ross JS, Fletcher JA. The HER/2neu oncogene: prognostic factor, predictive factor, and target for therapy. Semin Cancer Biol 1999; 9:125–138.

    Article  CAS  PubMed  Google Scholar 

  18. Lindahl T, Landberg G, Ahlgren J, Nordgren H, Norberg T, Klaar S, Holmberg L, Bergh J. Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer. Carcinogenesis. 2004; 25:375–380.

    Google Scholar 

  19. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci U S A 2001; 98:10869–10874.

    Article  CAS  Google Scholar 

  20. Van ‘t Veer LJ, De Jong D. The microarray way to tailored cancer treatment. Nat Med 2002; 8:13–14.

    Article  PubMed  Google Scholar 

  21. Van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347:1999–2009.

    Article  PubMed  Google Scholar 

  22. Pusztai L, Ayers M, Simmans FW, Damokosh A, Hess K, Valero V, Clark E, Ross J, Hortobagyi GN, Stec J. Emerging science: prospective validation of gene expression profiling-based prediction of complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer [abstract]. Proc Am Soc Clin Oncol 2003; 22:1.

    Google Scholar 

  23. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21:3357–3365.

    Article  PubMed  Google Scholar 

  24. Early Breast Cancer Trialists Group. Tamoxifen for early breast cancer: an overview of randomised trials. Lancet 1998; 351:1451–1467.

    PubMed  Google Scholar 

  25. Scottish Cancer Trials Breast Group. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Lancet 1993; 341:1293–1298.

    Article  PubMed  Google Scholar 

  26. Ejlertsen B, Dombernowsky P, Mouridsen H, Kamby C, Kjaeer M, Rose C, Andersen K, Jensen M, Bengtsson N, Bergh J. Comparable effect of ovarian ablation and CMF chemotherapy in premenopausal hormone receptor positive breast cancer patients. Proceedings of the American Society of Clinical Oncology 1999, Abstract 248.

  27. Early Breast Cancer Trialists’ Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 1996; 348:1189–1196.

    PubMed  Google Scholar 

  28. Rivkin S, Green S, O’Sullivan J, Cruz A, Abeloff M, Jewell W, Costanzi J, Farrar W, Osborne C. Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol 1996; 14:46–51.

    CAS  PubMed  Google Scholar 

  29. Davidson N, O’Neill A, Vukov A, Osborne C, Martino S, White D, Abeloff M. Effect of chemohormonal therapy in premenopausal, node positive, receptor positive breast cancer: an Eastern Cooperative Oncology Group Phase III Intergroup Trial (E5188, INT-0101). Proc Am Soc Clin Oncol 1999, Abstract 249.

  30. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T; The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003; 98:1802–1810.

    Article  CAS  PubMed  Google Scholar 

  31. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T, ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359:2131–2139.

    Article  PubMed  Google Scholar 

  32. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349:1793–1802.

    Article  CAS  PubMed  Google Scholar 

  33. Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Massobrio M, Benedetto C, Porpiglia M, Rinaldini M, Paladini G, Distante V, Franchi R, Failla G, Bordonaro R, Sismondi P, on behalf of the Italian Tamoxifen Arimidex (ITA) Trial. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment [abstract]. Breast Cancer Res Treat 2003; 82(s1):S6.

    Google Scholar 

  34. Combes LC, Hall E, Gibson LJ, Paridens R, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350:1081–1092.

    Article  PubMed  Google Scholar 

  35. Early Breast Cancer Trialists’ Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomised trials among 28,896 women. N Engl J Med 1988; 319:1681–1692.

    PubMed  Google Scholar 

  36. Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339:71–85.

    PubMed  Google Scholar 

  37. Early Breast Cancer Trialists Group. Polychemotherapy for early breast cancer; an overview of the randomised trials. Lancet 1998; 352:930–942.

    PubMed  Google Scholar 

  38. Early Breast Cancer Trialists’ Collaborative Group. 5th Annual Meeting of the Early Breast Cancer Trialists’ Collaborative Group, Oxford, UK, 21–22 September, 2000.

  39. Pritchard KI, Levine MN, Bramwell VHC, Shepherd LE, Tu D, Paul N. A randomized trial comparing CEF to CMF in premenopausal women with node positive breast cancer: update of NCIC CTG MA.5. Breast Cancer Res Treat 2002 [abstract 17].

  40. Poole CJ, Earl HM, Dunn JA, Hiller L, Bathers S, Spooner D, Grieve R, Agrawall RK, Foster E, Twelves C, for the NEAT and SCTBG Investigators. NEAT (National Epirubicin Adjuvant Trial) and SCTBG BR9601 (Scottish Cancer Trials Breast Group) phase III adjuvant breast trials show a significant relapse-free and overall survival advantage for sequential ECMF [abstract]. Proc Am Soc Clin Oncol 2003; 22:4.

    Google Scholar 

  41. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E III, Schilsky RL, Wood WC, Muss HB, Norton L. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21:976–983.

    Article  PubMed  Google Scholar 

  42. Mamounas EP, Bryant J, Lembersky BC, Fisher B, Atkins JN, Fehrenbacher L, Raich PC, Yothers G, Soran A, Wolmark N. Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28 [abstract]. Proc Am Soc Clin Oncol 2003; 22:4.

    Google Scholar 

  43. Buzdar AU, Singletary SE, Valero V, Booser DJ, Ibrahim NK, Rahman Z, Theriault RL, Walters R, Rivera E, Smith TL, Holmes FA, Hoy E, Frye DK, Manuel N, Kau SW, McNeese MD, Strom E, Thomas E, Hunt K, Ames F, Berry D, Hortobagyi GN. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res 2002; 8:1073–1079.

    CAS  PubMed  Google Scholar 

  44. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Hugh J, Nabholtz JM, Loret C, Rupin M, Blitz S, Riva A, Vogel C, On behalf of the BCIRG 001 Investigators. TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001:55 months follow-up. Breast Cancer Res Treat 2003; 82 Suppl 1:abstract 43.

  45. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21:1431–1439.

    Article  PubMed  Google Scholar 

  46. Rodenhuis S, Bontenbal M, Beex LV, et al. Netherlands Working Party on Autologous Transplantation in Solid Tumors: high-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 2003; 349:7–16.

    Article  CAS  PubMed  Google Scholar 

  47. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB Jr, Hoehn JL, Lees AW, Dimitrov NV, Bear HD. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16:2672–2685.

    CAS  PubMed  Google Scholar 

  48. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17:460–469.

    CAS  PubMed  Google Scholar 

  49. Pierga JY, Mouret E, Dieras V, Laurence V, Beuzeboc P, Dorval T, Palangie T, Jouve M, Vincent-Salomon A, Scholl S, Extra JM, Asselain B, Pouillart P. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer 2000; 83:1480–1487.

    Article  CAS  PubMed  Google Scholar 

  50. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK, Eggleton SP, Ogston KN. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002; 20:1456–1466.

    Article  CAS  PubMed  Google Scholar 

  51. Colleoni M, Minchella I, Mazzarol G, Nole F, Peruzzotti G, Rocca A, Viale G, Orlando L, Ferretti G, Curigliano G, Veronesi P, Intra M, Goldhirsch A. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol 2000; 11:1057–1059.

    Article  CAS  PubMed  Google Scholar 

  52. Buzdar AU, Valero V, Theriault RL, Frye D, Green M, Booser D, Guerra L, Sahin A, Ames F, Smith T, Singletary E, Hortobagyi G. Pathological complete response to chemotherapy is related to hormone receptor status. Breast Cancer Res Treat 2003; 82 Suppl 1:abstract 302.

  53. Green MC, Budzar AU, et al. Weekly paclitaxel followed by FAC in the neo-adjuvant setting provides improved pathologic complete remission rates compared to standard paclitaxel followed by FAC therapy—preliminary results of an ongoing prospective randomised trial. Proc Am Soc Clin Oncol 2001;20:abstract 129.

    Google Scholar 

  54. von Minckwitz G, Raab G, Blohmer JU, Gerber B, Lohr A, Costa SD, Eidtmann H, Hilfrich J, Jackisch C, Kaufmann M, the German Breast Group (GBG). In vivo chemosensitivity-adapted neoadjuvant chemotherapy (docetaxel-doxorubicin-cyclophosphamide followed by vinorelbine-capecitabine salvage therapy) in patients with primary breast cancer: results of the GEPAR-TRIO randomized pilot study. Breast Cancer Res Treat 2003; 82 Suppl 1:abstract 236.

  55. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, Wolmark N, National Surgical Adjuvant Breast and Bowel Project Protocol B-27. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003; 21:4165–4174.

    Article  PubMed  Google Scholar 

  56. Brito RA, Valero V, Buzdar AU, Booser DJ, Ames F, Strom E, Ross M, Theriault RL, Frye D, Kau SW, Asmar L, McNeese M, Singletary SE, Hortobagyi GN. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol 2001; 19:628–633.

    CAS  PubMed  Google Scholar 

  57. Perloff M, Lesnick GJ, Korzun A, Chu F, Holland JF, Thirlwell MP, Ellison RR, Carey RW, Leone L, Weinberg V, et al. Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: a Cancer and Leukemia Group B study. J Clin Oncol 1988; 6:261–269.

    CAS  PubMed  Google Scholar 

  58. Bartelink H, Rubens RD, van der Schueren E, Sylvester R. Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: a European Organization for Research and Treatment of Cancer Randomized Phase III Trial. J Clin Oncol 1997; 15:207–215.

    CAS  PubMed  Google Scholar 

  59. Ueno NT, Buzdar AU, Singletary SE, Ames FC, McNeese MD, Holmes FA, Theriault RL, Strom EA, Wasaff BJ, Asmar L, Frye D, Hortobagyi GN. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M.D. Anderson Cancer Center. Cancer Chemother Pharmacol 1997; 40:321–329.

    Article  CAS  PubMed  Google Scholar 

  60. Berg CD, Swain SM. Results of concomitantly administered chemoradiation for locally advanced non inflammatory breast cancer. Semin Radiat Oncol 1994; 4:226–235.

    PubMed  Google Scholar 

  61. Ellis MJ, Singh B, Miller WR, Llombart-Cussac A, Jänicke F, Mauriac L, Evans DB, Borgs M, Quebe-Fehling E, Brady C, Dugan M, Coop A. Letrozole (Femara) is a more effective inhibitor of estrogen activity than tamoxifen: evidence from a randomized phase III trial of 4 months preoperative endocrine therapy for postmenopausal women with primary invasive breast cancer. Proc Am Soc Clin Oncol 2001:abstract 1661.

  62. Zucali R, Uslenghi C, Kenda R, Bonadonna G. Natural history and survival of inoperable breast cancer treated with radiotherapy and radiotherapy followed radical mastectomy. Cancer 1976; 37:1422–1431.

    CAS  PubMed  Google Scholar 

  63. Hortobagyi GN, Ames FC, Budzar AU, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery and radiation therapy. Cancer 1988; 62:2507–2516.

    CAS  Google Scholar 

  64. Gradishar WJ. Inflammatory breast cancer: the evolution of multimodality treatment strategies. Semin Surg Oncol 1996; 12:352–363.

    Article  CAS  PubMed  Google Scholar 

  65. Baldini E, Gardin G, Giannessi PG, Evangelista G, Roncella M, Prochilo T, Collecchi P, Rosso R, Lionetto R, Bruzzi P, Mosca F, Conte PF. Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer. Ann Oncol 2003; 14:227–232.

    Article  CAS  PubMed  Google Scholar 

  66. Chia SKL, Speers C, Kang A, D’Yachkova Y, Malfair Taylor S, Barnett J, Coldman A, Gelmon K, Olivotto I. The impact of new chemotherapeutic and hormonal agents on the survival of women with metastatic breast cancer (MBC) in a population based cohort. Proc Am Soc Clin Oncol 2003; 22:abstract 22.

    Google Scholar 

  67. Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R, Combined Hormone Agents Trialists’ Group and the European Organization for Research and Treatment of Cancer. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. Clin Oncol 2001; 19:343–353.

    CAS  PubMed  Google Scholar 

  68. Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W, Wolter JM, Azab M, Webster A, Plourde PV. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol 1996; 14:2000–2011.

    CAS  PubMed  Google Scholar 

  69. Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A, Lee D. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998; 83:1142–1152.

    Article  CAS  PubMed  Google Scholar 

  70. Buzdar A, Douma J, Davidson N, Elledge R, Morgan M, Smith R, Porter L, Nabholtz J, Xiang X, Brady C. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001; 19:3357–3366.

    CAS  PubMed  Google Scholar 

  71. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, di Salle E, Arkhipov A, Piscitelli G, Miller LL, Massimini G. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000; 18:1399–1411.

    CAS  PubMed  Google Scholar 

  72. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomised trial. Arimidex Study Group. J Clin Oncol 2000; 18:3758–3776.

    CAS  PubMed  Google Scholar 

  73. Bonneterre J, Thurlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Webster A, Steinberg M, von Euler M. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. J Clin Oncol 2000; 18:3748–3757.

    CAS  PubMed  Google Scholar 

  74. Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thurlimann B, von Euler M, Sahmoud T, Webster A, Steinberg M. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001; 92:2247–2258.

    Article  CAS  PubMed  Google Scholar 

  75. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Janicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA, Dugan M. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19:2596–2606.

    CAS  PubMed  Google Scholar 

  76. Lonning PE, Bajetta E, Murray R, Tubiana-Hulin M, Eisenberg PD, Mickiewicz E, Celio L, Pitt P, Mita M, Aaronson NK, Fowst C, Arkhipov A, di Salle E, Polli A, Massimini G. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000; 18:2234–2244.

    CAS  PubMed  Google Scholar 

  77. Robertson JFR, Howell A, Abram P, Lichinitser MR, Elledge R. Fulvestrant versus tamoxifen for the first-line treatment of advanced breast cancer (ABC) in postmenopausal women. Ann Oncol 2002; 13:46.

    Google Scholar 

  78. Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, Kleeberg UR, Come SE, Vergote I, Gertler S, Buzdar A, Webster A, Morris C. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003; 98:229–238.

    Article  CAS  PubMed  Google Scholar 

  79. Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, Tinazzi A, Liberati A. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. Clin Oncol 1998; 16:3439–3460.

    CAS  PubMed  Google Scholar 

  80. Gennari A, Bruzzi P, Orlandini C, Salvadori B, Donati S, Landucci E, Guarneri V, Rondini M, Ricci S, Conte P. Activity of first line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy. Br J Cancer 2004; 90:962–967.

    Article  CAS  PubMed  Google Scholar 

  81. Pawan KS, Iliskovic N. Doxorubicin-induced cardiomiopathy. N Engl J Med 1998; 339:900–905.

    Article  PubMed  Google Scholar 

  82. Gennari A, Salvadori B, Donati S, Bengala C, Orlandini C, Danesi R, Del Tacca M, Bruzzi P, Conte PF. Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors. J Clin Oncol 1999; 17:3596–3602.

    CAS  PubMed  Google Scholar 

  83. Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JW, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PS, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Aapro M. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999; 17:1413–1424.

    CAS  PubMed  Google Scholar 

  84. Sjostrom J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lonn S, Bengtsson NO, Ostenstad B, Mjaaland I, Palm-Sjovall M, Wist E, Valvere V, Anderson H, Bergh J. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999; 35:1194–1201.

    Article  CAS  PubMed  Google Scholar 

  85. O’Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20:2812–2823.

    Article  PubMed  Google Scholar 

  86. O’Shaughnessy J, Nag S, Calderillo-Ruiz G, Jordaan J, Llombart A, Pluzanska A, Pawlicki M, Reyes JM, Sekhon J, Albain KS. Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): interim results of a global phase III study [abstract]. Proc Am Soc Clin Oncol 2003; 22:7.

    Google Scholar 

  87. Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S, Pienkowski T, Zaluski J, Pinter T, Krzakowski M, Vorobiof D, Leonard R, Kennedy I, Azli N, Murawsky M, Riva A, Pouillart P. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003; 21:968–975.

    Article  PubMed  Google Scholar 

  88. Mackey JR, Paterson A, Dirix LY, Dewar J, Chap L, Martin M, Chan S, Tang S-C, Dugan W, Gil M, Zaluski J, Russel C, Vogel C, Efremedis A, Appia F, Brunel E, Hatteville L, Azli N, Nabholtz JM. Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC) [abstract]. Proc Am Soc Clin Oncol 2002; 35:137.

    Google Scholar 

  89. Tubiana-Hulin M, Bonneterre J, Bougnoux P, Bonneterre M, Delozier T, Mayer F, Culine S, Dohollou N, Bendahmane B, Dieras V. Better survival with epirubicin-docetaxel (ET) combination as first-line chemotherapy in patients with metastatic breast cancer (MBC): final results of a phase II randomized study [abstract]. Proc Am Soc Clin Oncol 2003; 22:46.

    Google Scholar 

  90. Bontenbal M, Braun JJ, Creemers GJ, de Boer AC, Janssen JTP, Leys MBL, Schothorst KLC, Schmitz PIM, Bokma JJ, Seynaeve C. 1: Phase III study comparing AT (adriamycin, docetaxel) to FAC (fluorouracil, adriamycin, cyclophosphamide) as first-line chemotherapy (CT) in patients with metastatic breast cancer (MBC). Eur J Cancer Suppl 2003; 1 No. 5:S201.

  91. Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel, as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003; 21:588–592.

    Article  PubMed  Google Scholar 

  92. Luck HJ, Thomssen C, Untch M, et al. Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC): epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC): a study of the AGO Breast Cancer Group [abstract]. Proc Am Soc Clin Oncol 2000; 19:73a.

    Google Scholar 

  93. Carmichael J. UKCCCR trial of epirubicin and cyclophosphamide (EC) vs. epirubicin and taxol (ET) in the first line treatment of women with metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol 2001; 20:22a.

    Google Scholar 

  94. Jassem J, Pienkowski T, Pluzanska A, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III multicenter trial. J Clin Oncol 2001; 19:1707–1715.

    CAS  PubMed  Google Scholar 

  95. Bonneterre J, Dieras V, Tubiana-Hulin M, et al. 6 cycles of epirubicin/docetaxel (ET) versus 6 cycles of 5FU/epirubicin/cyclophosphamide (FEC) as first line metastatic breast cancer (MBC) treatment. Proc Am Soc Clin Oncol 2001; 20:42a.

    Google Scholar 

  96. Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, Gamucci T, Twelves C, Fargeot P, Epelbaum R, Lohrisch C, Piccart MJ. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol 2002; 20:3114–3121.

    Article  CAS  PubMed  Google Scholar 

  97. Ghersi D, Wilcken N, Simes J, Donoghue E. Taxane containing regimens for metastatic breast cancer. The Cochrane Library 2003:issue 3.

  98. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783–792.

    CAS  PubMed  Google Scholar 

  99. Gennari A, Bruzzi P, Orlandini C, Landucci E, Donati S, Salvatori B, Baldini E, Rondini M, Dani C, Conte PF. Paclitaxel containing first line chemotherapy (CT) is an independent predictive factor of survival in metastatic breast cancer (MBC): results of a multivariate analysis on 640 patients [abstract]. Ann Oncol 2002; 13 Suppl 5:46.

    Google Scholar 

  100. Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001; 19:4216–4223.

    CAS  PubMed  Google Scholar 

  101. Zelek L, Barthier S, Riofrio M, Fizazi K, Rixe O, Delord JP, Le Cesne A, Spielmann M. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 2001; 92:2267–2272.

    Article  CAS  PubMed  Google Scholar 

  102. Mey U, Gorschluter M, Ziske C, Kleinschmidt R, Glasmacher A, Schmidt-Wolf IG. Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial. Anticancer Drugs 2003; 14:233–238.

    Article  CAS  PubMed  Google Scholar 

  103. Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, Osterwalder B. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001; 92:1759–1768.

    Article  CAS  PubMed  Google Scholar 

  104. Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Seaman JJ, Knight RD, Heffernan M, Mellars K, Reitsma DJ. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998; 16:2038–2044.

    CAS  PubMed  Google Scholar 

  105. Conte PF, Latreille J, Mauriac L, Calabresi F, Santos R, Campos D, Bonneterre J, Francini G, Ford JM. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol 1996; 14:2552–2559.

    CAS  PubMed  Google Scholar 

  106. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98:1735–1744.

    Article  CAS  PubMed  Google Scholar 

  107. Hilner BE, Ingle JN, Chelbowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. Clin Oncol 2003; 21:4042–4057.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena, Italy

    Valentina Guarneri & Pier Franco Conte

Authors
  1. Valentina Guarneri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pier Franco Conte
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pier Franco Conte.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Guarneri, V., Conte, P.F. The curability of breast cancer and the treatment of advanced disease. Eur J Nucl Med Mol Imaging 31 (Suppl 1), S149–S161 (2004). https://doi.org/10.1007/s00259-004-1538-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-004-1538-5

Keywords

Search

Navigation